MED Stock Recent News

LifeMD Inc (NASDAQ:LFMD) stock traded higher in Wednesday's early trade, up 11% to $8.99, as the health company announced an agreement with Medifast Inc (NYSE:MED), which sees the new partners working to develop a clinically supported weight management program, featuring GLP-1 medications. GLP-1 (glucagon-like peptide 1) based drugs – which include Novo Nordisk (NYSE:NVO)'s Ozempic -have quickly been adopted as something of a ‘blockbuster' for obesity and weight loss treatments, among an emerging list of other ailments.

The companies are teaming up to offer a ‘transformative weight management solution.'

LifeMD Inc.'s stock LFMD, +1.76% soared 9% early Wednesday, after the virtual primary care provider said it's teaming up with Medifast Inc. MED, +1.03%, a wellness company known for its habit-based and coach-guided lifestyle service Optavia, to create a clinically supported weight management program that will include the new class of weight-loss drugs called GLP-1. The drugs developed by Eli Lilly & Co. LLY, +0.12% and Denmark's Novo Nordisk NVO, -0.46% NOVO.B, +1.18% are named after a gut hormone that they mimic to control blood sugar have become highly popular and have even suffered shortages in the past year.

Medifast (MED) is proactively positioning itself to tap into the increasing demand for weight loss medications, showcasing a commitment to staying in touch with market trends.

Medifast's (MED) Q3 results reflect challenges in customer acquisition. However, cost-reduction efforts and efficiency improvements as part of the "Fuel for the Future" plan bode well.

Medifast, Inc. (NYSE:MED ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Steven Zenker - Vice President of Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants Linda Bolton Weiser - D.A. Davidson Jim Salera - Stephens Inc. Doug Lane - Water Tower Research Operator Greetings.

Medifast's (MED) third-quarter results are likely to reflect concerns surrounding customer acquisition amid a challenging landscape. However, a focus on growth plans bodes well.

Medifast's (MED) OPTAVIA program is a robust and adaptable solution focused on health and wellness. This holistic approach positions it for sustained long-term growth.

Medifast (MED) reported earnings 30 days ago. What's next for the stock?

Medifast's (MED) second-quarter 2023 results reflect lower sales and earnings on reduced Coach productivity and cost inflation.